Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
This study addresses the importance of the <i>DPYD</i> analysis implementation in clinical practice after the changes in EMA and AEMPs recommendations which has led to a significant increase in <i>DPYD</i> genotyping requests. This highlights the significance of preemptive genotyping for accurately adjusting fluoropyrimidines doses before initiating treatment.
Authors
- Olalla Maroñas (ORCID: https://orcid.org/0000-0001-6952-3377)
- Francisco Barros (ORCID: https://orcid.org/0000-0001-6895-4140)
- Ãngel Carracedo (ORCID: https://orcid.org/0000-0003-1085-8986)
- Almudena Gil-Rodríguez (ORCID: https://orcid.org/0000-0002-7637-6915)
- Sheila Recarey-Rama (ORCID: https://orcid.org/0009-0003-1623-1110)
- Ana Rodríguez-Viyuela
Institutions
- Universidade de Santiago de Compostela (ES)
- Instituto de Salud Carlos III (ES)
- Centre for Biomedical Network Research on Rare Diseases (ES)
- Fundación Pública Galega de Medicina Xenómica (ES)
- Instituto de Investigación Sanitaria de Santiago (ES)
- Servicio Gallego de Salud (ES)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-28
- DOI
- https://doi.org/10.3389/fphar.2025.1523536
- Citations
- 3
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 5.45